Charles Schwab Investment Management Inc. Acquires 57,677 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Charles Schwab Investment Management Inc. boosted its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 5.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,134,651 shares of the medical research company’s stock after purchasing an additional 57,677 shares during the period. Charles Schwab Investment Management Inc. owned about 0.88% of NeoGenomics worth $16,736,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in NEO. Segall Bryant & Hamill LLC grew its position in shares of NeoGenomics by 67.0% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock valued at $27,928,000 after acquiring an additional 759,524 shares during the period. First Light Asset Management LLC grew its position in shares of NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after acquiring an additional 480,396 shares during the period. Dimensional Fund Advisors LP grew its position in shares of NeoGenomics by 7.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after acquiring an additional 217,687 shares during the period. American Century Companies Inc. grew its position in shares of NeoGenomics by 5.4% in the 2nd quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after acquiring an additional 167,145 shares during the period. Finally, Sei Investments Co. grew its position in shares of NeoGenomics by 152.6% in the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock valued at $3,658,000 after acquiring an additional 159,350 shares during the period. Institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

NEO has been the subject of a number of research reports. Benchmark restated a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, November 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.25.

NeoGenomics Price Performance

Shares of NeoGenomics stock opened at $17.76 on Friday. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $21.22. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The company has a 50-day simple moving average of $15.01 and a two-hundred day simple moving average of $15.00. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -29.11 and a beta of 1.24.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.06) EPS. Analysts forecast that NeoGenomics, Inc. will post -0.17 EPS for the current year.

Insider Activity

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.